My Companies
Notification
Account
Log Out
Login
Deepak Sapra resigned as CEO, API and Services, and senior management personnel to pursue external opportunities. He will remain through November 12, 2026, supporting transition after more than 23 years with Dr. Reddy’s.
Dr. Reddy's Receives US FDA Approval For Rituximab Biosimilar
Dr Reddy's Receives US FDA Form 483 With Seven Observations At Biologics Plant
Dr. Reddy's Biologics Plant Receives US FDA Form 483 With Seven Observations
Dr. Reddy's Receives USFDA Form 483 With Seven Observations at Biologics Plant